Cipla Limited: CSR spending FY 2021-22 to 2025-26
Cipla Limited spent ₹343.07 crore on CSR from FY 2021-22 to 2025-26 (standalone company, from its annual reports), shown year by year with the money set aside for ongoing projects.
FY 2025-26
In FY 2025-26 Cipla Limited spent ₹82.69 crore on CSR against a 2% obligation of ₹94.73 crore, and set aside ₹12.04 crore for ongoing projects.
Period: Apr 2025 - Mar 2026.
- Obligation (2% rule): ₹94.73 crore
- Spent in the year: ₹82.69 crore (projects ₹82.39 crore, admin overheads ₹0 crore, impact assessment ₹0.3 crore)
- Set aside for ongoing projects (Unspent CSR Account): ₹12.04 crore
- Transferred to a Schedule VII fund: not disclosed
- Excess from earlier years set off against this year's obligation: ₹0.69 crore
- Environment spend: not disclosed
Main programmes
- Unspent CSR of 12.04 cr (ongoing projects) moved to the Unspent CSR Account on 29 Apr 2026: skilling institutes of Foundation for Pharmaceutical Academy for Global Excellence (PAGE) in Ahmedabad and Hyderabad (construction awaiting plan approval), and specialised medical equipment for IISc Bengaluru (overseas procurement delays)
- Board-approved FY26 plan: palliative care - Cipla Palliative Centre (Pune) and partner-run home-based/OPD palliative care across 17 states/UTs
- Board-approved FY26 plan: community health - maternal and child health, pulmonary rehabilitation/COPD, thalassemia support, public hospital equipment; Pulmonary Medicine Dept at TATA IISc Medical School, Bengaluru
- Board-approved FY26 plan: Public System Partnership for maternal and newborn health in Mumbai slums; Mobile Health Vans in Madhya Pradesh, Himachal Pradesh, Maharashtra, Karnataka
- Board-approved FY26 plan: education - mobile science vans, science labs, digital learning (DLEAD), scholarships, Balvatika centres in 6 states
- Board-approved FY26 plan: skilling - Indian Pharmaceutical Alliance pharma skilling institute (Gujarat, Sikkim, Uttar Pradesh, Maharashtra); internships
- Board-approved FY26 plan: environment - small water body rejuvenation, renewable energy and sustainable agriculture; restoration of 100 sq. km of Ujjani Dam wetland
- Capital assets created or acquired through CSR in the year: 297 (details in separate exhibit, not fetched)
Trees and greening
- Planned: restoration of selected 100 sq. km area of Ujjani Dam wetland (conservation and sustainable management); plantations near plant locations under water rejuvenation programme (amount not disclosed)
States: Maharashtra, Madhya Pradesh, Himachal Pradesh, Goa, Karnataka, Sikkim, Uttar Pradesh, Rajasthan, Gujarat, Telangana, Andhra Pradesh, Tamil Nadu, Kerala, Punjab, Haryana, Bihar, West Bengal, Assam, Jammu and Kashmir.
Implementing agencies: Cipla Foundation, Cipla Limited (direct), Foundation for Pharmaceutical Academy for Global Excellence (PAGE), Indian Institute of Science (IISc), Bengaluru, Indian Pharmaceutical Alliance.
Source: S1 Cipla Integrated Annual Report 2025-26 (NSE archive copy; CSR annexure pdf pp.169-174, printed pp.151-156; Note 48 pdf p.338), pages 169-174, 338
Sources: Cipla Integrated Annual Report 2025-26 (NSE archive copy; CSR annexure pdf pp.169-174, printed pp.151-156; Note 48 pdf p.338) – Cipla Limited; Cipla Annual Report 2024-25 (CSR annexure pdf pp.155-160) – Cipla Limited; Cipla Annual Report 2023-24 (CSR annexure pdf pp.169-172; Note 46) – Cipla Limited; Cipla Annual Report 2022-23 (CSR annexure pdf pp.130-133) – Cipla Limited; Cipla Annual Report 2021-22 (BSE copy; CSR annexure pdf pp.132-137; Note 45) – Cipla Limited; Cipla Annual Action Plan / CSR projects FY 2024-25 (v6.0) – Cipla Limited; Cipla CSR Projects FY 2025-26 (v3.0) – Cipla Limited; Cipla Approved CSR Projects 2023-24 (v6.0) – Cipla Limited
Plan your company's CSR tree planting with GreenEye
GreenEye Foundation (GEYE INNOVATION FOUNDATION) is a Section 8 non-profit registered for CSR (CSR-1 registration CSR00881842), with 12AB and 80G registration. Companies can fund tree planting with GreenEye and get geotagged photos, a tracking link and a certificate for every tree.
Talk to usShare this article